Title
Pulmonary overlap syndromes, with a focus on COPD and ILD

Permalink
https://escholarship.org/uc/item/7d14k366

Journal
Sleep Medicine Clinics, 9(3)

ISSN
1556-407X

Authors
Dudley, KA
Owens, RL
Malhotra, A

Publication Date
2014

DOI
10.1016/j.jsmc.2014.05.008

Peer reviewed
First described in the 1980s by pulmonologist David Flenley,1 overlap syndromes (OVSs) refer to the coexistence of chronic lung disease and obstructive sleep apnea (OSA) in the same patient. To date, overlap syndromes have been poorly studied for a variety of reasons.

Nevertheless, recent data in chronic obstructive pulmonary disease (COPD) and patients with OSA overlap highlight the increased morbidity and mortality of overlap syndromes compared with either underlying disorder alone.

The underlying disorders in overlap syndrome (OSA and chronic lung disease) may be of very different severity. Thus, there is a great amount of patient heterogeneity; the goals of therapy may differ in different patients.

Unrecognized OSA may contribute to symptoms of sleepiness and fatigue in those patients with chronic lung disease. Thus, clinicians should be mindful of the overlap syndromes in these patients.

OVS does, as Flenley thought, have worse outcomes than either disease in isolation. These findings have highlighted the urgent need for further study of both the OVS and all overlaps between OSA and chronic lung disease.

CLINICAL AND RESEARCH CHALLENGES OF THE OVS

OVSs are poorly understood for many reasons. Using the OVS as a prototype

1. The diagnosis of OVS is nebulous, as both OSA and COPD are heterogeneous disorders. COPD and OSA both have wide ranges of severity, in terms of both objective measurements of disease (eg, forced expiratory volume in 1 second [FEV₁], and apnea-hypopnea index [AHI]) and patient-reported symptoms (eg,
dyspnea and daytime tiredness). OVS is defined by the presence of both conditions regardless of the relative burden of one or the other. Therefore, patients with OVS may represent a very heterogeneous population, falling into one of many potential categories: mild COPD with mild OSA, mild COPD with severe OSA, severe COPD with mild OSA, severe COPD with severe OSA, and so forth. Prognosis and treatment, therefore, could be considerably different depending on the relative impact of each condition. Although it is a minor point, there is not a single International Classification of Diseases, Ninth Revision code for OVS, which impedes even epidemiologic research.

2. The diagnosis of OSA in the setting of hypoxic lung disease is uncertain. The definition of OSA includes hypopneas and reductions in airflow with associated desaturation, which is more likely to occur in those with chronic lung disease. The AHl, used to grade OSA severity, does not differentiate between apneas and hypopneas. Thus, a patient with severe COPD might have the same AHl consistent with severe OSA (based on a large number of hypopneas) as another patient with a very collapsible upper airway without lung disease (who predominantly has apneas). In addition, a 10-minute prolonged desaturation caused by hypoventilation may be scored as a single hypopnea because the event duration has minimal effect on the definitions used. More rigorous definitions of OSA might be useful, such as the apnea index or scoring based on airflow alone and arousals independent of oxygen desaturation.

3. The interactions of COPD and OSA are not understood. Thus, it is unknown at a pathophysiologic level whether each disorder might predispose to the other disease. As discussed earlier, the baseline hypoxemia of COPD likely predisposes to a diagnosis of OSA. But other links are possible; for example, the changes in lung volumes that occur with COPD might impact upper airway collapsibility. How COPD and OSA interact to cause the increased morbidity and mortality attributable to OVS is not known. Is it simply from more prolonged hypoxemia or hypercapnia than either disorder alone? Or are poor outcomes caused by the indirect effects of the disorders, such as cardiovascular disease?

4. Thus, the goals of therapy in OVS are poorly defined. For a patient with severe OSA with many apneas, the goal of therapy may be to support patency of the upper airway and eliminate apneic events. For a patient with evidence of hypoventilation, the goal may be to improve nocturnal gas exchange and hypercarbia. Maybe the best approach would be intensive modification of cardiovascular risk factors (eg, blood pressure, cholesterol modification). These uncertainties contribute to the confusion as to the ideal therapy to use.

5. The optimal treatment of OVS is unknown. Few large clinical trials have been undertaken, and no large studies have compared long-term outcomes between randomized therapies. Although continuous positive airway pressure (CPAP) is the most commonly applied therapy, some groups have used bilevel positive airway pressure, which provides a higher pressure during inspiration than during expiration. Bilevel may have benefits over CPAP for some patients, particularly among patients with severe COPD whereby it may aid with nocturnal ventilation and resting of respiratory muscles. Finally, the role of oxygen therapy, another treatment used clinically, has not been fully explored in this population. The role of medical therapy aimed at limiting cardiovascular events has also not been explored.

6. An additional under-recognized consideration is that sleep is poor in chronic lung diseases, independent of upper airway collapse. Many studies have highlighted the high prevalence of sleep complaints among patients with chronic lung diseases. There are many reasons behind this finding, ranging from cough interfering with sleep, increased anxiety and insomnia, side effects of medications (eg, chronic glucocorticoids, beta agonists), and frequent arousals. Although treatment of OVS with CPAP may improve upper airway patency, CPAP will not address many of the nonrespiratory problems that plague sleep in this population. Thus, CPAP adherence may be challenged in ways that are unique compared with those without chronic lung disease.

These points are illustrated as the authors discuss what is known about OVS (and OSA and idiopathic pulmonary fibrosis [IPF]), perhaps the most common of the interstitial lung diseases (ILDs).

**COPD AND OSA**

Throughout this section, OVS refers exclusively to those with COPD and OSA.

**COPD**

COPD is a progressive lung disease characterized by irreversible airway obstruction (FEV1/forced...
Pulmonary Overlap Syndromes

vital capacity [FVC]<70%). This disease can involve the small airways, pulmonary parenchyma, or both. COPD results from an inflammatory response that can result in chronic sputum production (chronic bronchitis) as well as the destruction of alveolar walls distal to the terminal bronchioles, leading to enlargement of the airspaces (emphysema). Although tobacco use is strongly associated with the development of COPD, it is not the only risk factor. In developing countries, exposure to indoor air pollution plays a critical role, in particular as a result of fuels burned for cooking and heating. Occupational causes are also well described, such as irritants and fumes. Estimates are now that most COPD worldwide is non-smoking related, emphasizing caution about labeling the disease as self-inflicted. COPD may present as dyspnea, wheezing, cough, sputum production, poor exercise tolerance, hypoxic and/or hypercarbic respiratory failure, and right heart failure (cor pulmonale). There are Global Initiative for Chronic Obstructive Lung Disease (GOLD)–defined stages of disease severity based on pulmonary function testing (the FEV1) and symptoms. In the United States, more than 5% of the population (at least 13.7 million people) is burdened by COPD,2,3 which is a leading cause of morbidity. Worldwide, about 10% of the population is affected.4 Although medications may improve symptomatic control of the disease and slow progression, the health-related consequences of COPD remain high.3 As of 2011, COPD was the third leading cause of death in the United States.5 Annual expenditures for the disease are approaching $40 billion when direct and indirect costs are considered.6

Although COPD is often considered a respiratory condition, the impact on other organ systems and overall health is increasingly well recognized. The most recent GOLD definition of the disease highlights COPD as a systemic process with “significant extrapulmonary effects that may contribute to the severity in individual patients.”7 Indeed, depression, skeletal-muscle myopathy, anemia, and osteoporosis are all common in COPD. Similarly, as is discussed later, sleep disturbance and its consequences could be thought of as one of these extrapulmonary manifestations. COPD is also associated with adverse cardiac outcomes, which may be of particularly importance when thinking about the overlap with OSA, which also has cardiovascular consequences.8–12 Even after consideration of shared risk factors, such as cigarette smoking, COPD is associated with higher rates of coronary artery disease, congestive heart failure, and arrhythmias.13,14 Additional mechanisms by which COPD may play a role in cardiovascular disease include increased oxidative stress, inflammation, and increased platelet activation.

Of particular interest in the current discussion, COPD is a heterogeneous disorder, with variable amounts of airway and parenchymal disease. Most patients have a predominance of one phenotype, though there is usually some overlap. In the past, patients with chronic bronchitis were described as blue bloaters, referring to hypoxemia, polycythemia, and cor pulmonale that often accompanies patients with this form of COPD. Pink puffers were those with an emphysematous phenotype of COPD, often with muscle wasting and hyperinflation but without oxygen desaturation.

The mechanisms behind the sleep disturbances are likely multifactorial. Symptoms such as cough and wheezing may play a role as noted earlier.26,29 Recent work has also highlighted nonrespiratory factors that also perturb sleep among patients with COPD.30 For example, restless leg syndrome

Sleep and COPD

More than three-quarters of patients with COPD report bothersome nocturnal symptoms, such as dyspnea.15,16 Patients who report cough and wheeze during the day are more likely to have sleep disturbances than those who do not.17 Patients report trouble falling asleep, frequent awakening, difficulty returning to sleep, and nonrestorative sleep. In a survey of patients with COPD, more than 60% had experienced at least one sleep symptom in the preceding 28 days.15 Rates of clinical insomnia are high among patients with COPD, present in more than one-fourth.18 As compared with controls, COPD confers an increased risk of insomnia nearly twice that of non-COPD patients.19 These sleep disturbances are chronic, persisting over many years.20

Sleep complaints increase with more severe disease. Although mild obstructive lung disease is associated with preserved sleep quality,21 a more severe obstructive disease is associated with increased sleep complaints.22 Severe disease negatively impacts several objective sleep parameters, such as total sleep time, sleep efficiency, rapid eye movement (REM) sleep,23 as well as sleep-onset latency, arousals, and sleep-stage transitions.24–27

The mechanisms behind the sleep disturbances are likely multifactorial. Symptoms such as cough and wheezing may play a role as noted earlier.26,29 Recent work has also highlighted nonrespiratory factors that also perturb sleep among patients with COPD.30 For example, restless leg syndrome
has been found in up to one-third of patients with COPD, and periodic limb movements are associated with worse insomnia. As a result of all of these factors, the use of medications to aid sleep is common, especially sedative hypnotics, which are used by 25% of patients with COPD. Although data are sparse, these medications could theoretically worsen hypoxemia/hypercapnia, though this may not be true for all patients.

Changes in Respiration During Sleep with COPD and Nocturnal Oxygen Desaturation

Nocturnal oxygen desaturation (NOD) in chronic lung disease is the result of the normal changes that occur in ventilation with sleep. Put another way, sleep is a stress test for those patients with chronic lung disease that leads to nocturnal hypoxemia and hypercapnia. Understanding the normal changes in respiration that occur with sleep is key to understanding NOD.

Normal Changes in Respiration During Sleep

Sleep is divided into different stages based on electroencephalography waveforms, muscle tone, eye movement, and breathing pattern, with the main distinction being between non-REM sleep and REM sleep. The main respiratory changes that occur during sleep are a decrease in ventilation (largely a decrease in tidal volume without a compensatory increase in respiratory rate) and decreased accessory muscle activity. The changes in respiration are most pronounced in REM sleep, which is notable for skeletal muscle hypotonia (with the exception of certain muscles, including the diaphragm); in addition to decreased ventilation, the breathing pattern becomes very irregular (especially during bursts of REMs). The decrease in respiratory drive reflects both a decrease in metabolic rate, which results in less carbon dioxide (CO₂) production, and, thus, requirement for elimination, and an increase in the CO₂ set point. The reduction in minute ventilation is further pronounced during REM, when ventilation may be 40% less compared with wakefulness. In addition to the decrease in the respiratory set point, there is decreased responsiveness to hypercapnia and hypoxia compared with wakefulness. Finally, upper airway resistance increases during sleep, even in those without OSA. An overview of the changes is outlined in Fig. 1.

Sleep and Breathing with COPD

All of the aforementioned changes are physiologic changes that occur from wakefulness to sleep. However, in the presence of lung disease, the consequences may be dramatic and lead to oxygen desaturation. First, these patients may already have borderline hypoxemia, which puts them on the steep part of the oxygen hemoglobin binding curve; that is, small changes in PaO₂ lead to a decrease in oxygen saturation. Second, patients with COPD have increased minute ventilation for a variety of reasons and frequently rely on accessory muscles to aid ventilation. As a result, ventilation can decrease dramatically during sleep and particularly in REM sleep when muscle activity...
decreases. Furthermore, patients with COPD may have chest hyperinflation, which stretches the diaphragm and impairs contractile function.43

NOD is perhaps the most common sleep abnormality attributed to COPD, occurring in anywhere from one-quarter to three-quarters of patients with an awake oxygen saturation greater than 90% to 95%.44–46 During sleep, desaturations are frequent among patients with an FEV1/FVC less than 65%21; increasing severity of obstructive disease is associated with more severe desaturations during sleep. Among those with severe obstructive lung disease (FEV1<30%), a 20% decrease of oxygen saturation can be seen during non-REM sleep and an impressive decline of 40% during REM.32 There is substantial variation in reported NOD rates, in part caused by the heterogeneous nature of COPD as well as the definition of NOD, which may be based either on nadir levels or the duration of low oxygen tension.

COPD and OSA: the OVS

OSA is a common disorder, characterized by partial or complete collapse of the upper airway during sleep, resulting in intermittent hypoxia and arousals. The repetitive nature of these breathing events results in fragmented and nonrestorative sleep. Among middle-aged men (50–70 years old), the prevalence of moderate to severe OSA is predicted to be as high as 17% and slightly lower but still concerning at 9% among middle-aged women.47 OSA is associated with an increased risk of serious neurocognitive and cardiovascular consequences, including hypertension, congestive heart failure, and stroke.48–51 CPAP is the gold standard treatment of OSA and consists of a mask worn during sleep connected to a machine that delivers pressurized air, thereby splinting open the airway during sleep. Although CPAP is efficacious in treating OSA in almost all cases, its effectiveness is limited by patient adherence. Although adherence rates may be improved through intensive support and behavioral therapy, the real-world nonadherence rates may approach 50%. In the context of OVS, these facts illustrate the potentially large number of patients with OSA at risk for OVS, that both OSA and COPD have substantial cardiovascular morbidity and mortality, and that positive airway pressure is unlikely to be accepted by many patients.

Diagnosing OSA Among Those Patients with COPD

OSA is diagnosed through polysomnography, with apneas and hypopneas recorded during sleep. The tendency toward oxygen desaturation described earlier in those patients with chronic lung disease impacts the diagnosis of OSA. Although the designation of apneas is straightforward and independent of oxygen desaturation, hypopneas are based on flow limitation of at least 30% and require either an accompanying 3% or greater oxygen desaturation or an arousal. Based on the sigmoidal shape of the oxygen-hemoglobin desaturation curve, any small change in PaO2 that occurs during sleep will be reflected as a larger (scorable) change in oxygen saturation. Put another way, 2 patients with the same upper airway tendency to collapse, but one healthy and the other with chronic lung disease, might have very different apnea-hypopnea indices. A similar observation that makes the same point is that the AHI improves with descent from altitude, largely because of a decrease in the number of hypopneas.52 Nevertheless, there are no current alternative scoring criteria or guidelines for OSA diagnosis in the setting of chronic lung disease.

Among patients with COPD, there are clues to suggest OSA beyond the classic symptoms of snoring, witnessed apneas, and daytime sleepiness. For example, headaches with the initiation of nocturnal supplemental oxygen suggest coexistent OSA (caused by increased hypercapnia). Hypercapnia, despite relatively preserved pulmonary function tests, may also signal the presence of sleep-disordered breathing and prompt evaluation. Indeed, based on findings from one cohort, FEV1 was severely decreased among patients with COPD only with hypercapnia but only moderately reduced in patients who had both COPD and OSA. Despite this difference in pulmonary function tests, daytime PaCO2 was higher among those with OVS compared with COPD only.53,54 Additionally, obesity is more common among hypercarbic patients with COPD who have OSA as compared with COPD only.55 For comparison, the characteristics of COPD alone, OSA alone, and OVS from one cohort are outlined in Table 1.

The American Thoracic Society/European Respiratory Society’s guidelines also highlight the role of referring for overnight testing among those with mild COPD and evidence of pulmonary hypertension. Although only 16% of patients with OSA have been observed to have pulmonary hypertension, this number jumps to 86% for those with OVS.55 This is an intriguing finding, given that traditional markers of OSA severity and nocturnal hypoxia in COPD are not predictive of pulmonary hypertension. However, time spent with oxygen desaturation less than 90% is high among patients with OVS, even without a severe obstructive pattern on spirometry.
In general, small studies from the early 1990s suggested that severe COPD was a risk factor for OSA. For example, one early study found greater than 80% prevalence of OSA among patients with COPD and excessive daytime sleepiness referred for evaluation. In certain populations, too, such as Veterans Administration patients, the coexistence of OSA and COPD was high (29%) among patients who had polysomnogram and spirometry as part of their evaluation.

More recently, larger epidemiology studies including a more broad range of subjects, such as the Sleep Heart Health Study and Multinational Monitoring of Trends and Determinants in Cardiovascular Disease, have not demonstrated an increased risk of OSA among those with obstructive lung disease, at least among those with mild obstructive lung disease. In these large cohorts, the prevalence of OSA was 11% to 14%, which was similar in those with or without obstructive lung disease. Thus, it seems likely that there is little connection among those with mild COPD; whether more severe COPD can contribute to OSA is not clear.

Although the answer is not yet known, proposed mechanisms of OSA risk in severe COPD include the following: fluid shifts in those with cor pulmonale from lower extremity edema to the neck, a generalized myopathy from COPD alone that affects the upper airway muscles, or a steroid-induced myopathy from systemic or inhaled corticosteroids. All of these changes would increase upper airway collapsibility.

**Clinical Consequences of OSA and COPD**

The large aforementioned cohort studies did highlight that among those with obstructive lung disease and OSA, the nocturnal desaturations and sleep disturbances are greater (both oxygen saturation nadir and duration of hypoxemia) than would be expected for either disease alone. Whether causal or not, more recent reports have suggested an increased mortality in OVS compared with COPD and OSA alone and have increased awareness about OVSs. First, Marin and colleagues found decreased survival among patients with OVS compared with either COPD or OSA alone (Fig. 2). There were differences in death from any cause and cardiovascular causes when patients with OVS using CPAP were compared with those not on CPAP. No differences were seen between COPD only and patients with OVS using CPAP. That patients with OVS using CPAP have reduced mortality compared with OVS without CPAP has now also been reported in other cohorts.

Jaoude and colleagues found that CPAP only improved outcomes from OVS in those patients.
who were also hypercapnic. Further exploring the observed therapeutic benefit of CPAP, Stanchina and colleagues\(^6^3\) found that greater time on CPAP was associated with reduced mortality in patients with OVS.

Although the improvement with CPAP seems dramatic, these are not randomized data; these were cohort studies in which subjects chose to adhere to or abandon CPAP therapy. Patients who did not adhere to CPAP may have been those with more COPD/less OSA; had more respiratory symptoms, such as dyspnea or sputum that limit CPAP use; or were less likely to adhere to other medication therapy, which is also important for limiting poor outcomes (eg, statin therapy). Nevertheless, these findings highlight the need to focus more resources on the care and understanding of these patients.

It is assumed, but not known, that the worse outcomes in OVS are caused by excess cardiovascular events. As discussed earlier, both COPD and OSA increase cardiovascular risk. Some data support this potential mechanism, suggesting that OSA can augment vascular changes among patients with COPD, such as arterial stiffness.\(^6^5\) Sharma and colleagues\(^6^6\) found that patients with OSA have more extensive remodeling of the right ventricle seen on cardiac magnetic resonance compared with those with COPD alone; the extent of right ventricle remodeling was correlated with the oxygen desaturation index.

### Treatment of OVS

Treatment of OVS may be thought of as addressing the underlying COPD, OSA, or both. Although the specific goals of treatment remain poorly defined, most clinicians strive to eliminate sleep-disordered breathing and eliminate NOD. What to target for ideal oxygen saturation, however, remains unclear, as does the impact of normalizing hypercapnia. The most commonly applied therapy is CPAP.

Before CPAP is applied, however, it is critical to consider the use of therapies that target the underlying COPD, such as bronchodilators and antiinflammatories. Therapies aimed at COPD alone can improve nocturnal oxygen saturation as well as decrease symptoms. Ipratropium and tiotropium, cholinergic bronchodilators, long-acting beta-agonists, and oral steroids all have data to support improvements in oxygen saturation during sleep.\(^6^7\)–\(^7^0\) Some of these agents, such as ipratropium, have also been shown to improve sleep quality and increase REM and total sleep time, although, surprisingly, tiotropium did not.\(^6^7\)\(^,\)\(^6^8\)\(^,\)\(^7^0\)

Although the mechanism of these improvements has yet to be teased out, these studies suggest that optimizing COPD treatment can play a key role in the degree of nocturnal oxygen saturation. The impact on upper airway patency is unknown; some have hypothesized that (inhaled) steroids might predispose the upper airway to myopathy and increased collapsibility. However, at least in asthmatic patients receiving high-dose inhaled corticosteroids, there was no increase in collapsibility.\(^7^1\)

Nocturnal oxygen is a mainstay of therapy for hypoxemia in COPD with demonstrated mortality benefits.\(^7^2\)\(^,\)\(^7^3\) Among patients with OSA, nocturnal oxygen therapy alone may improve hypoxemia; however, arousals, sleep architecture, and daytime symptoms, such as sleepiness, are not impacted,\(^7^4\) pointing to the potential impact of sleep fragmentation caused by arousals triggered by airway obstruction, which is not addressed by oxygen therapy. Thus, supplemental oxygen alone for OSA seems unlikely to be of benefit.

### CPAP and Lung Function in COPD

There are a few studies that have assessed treatment with CPAP in patients with OVS. Small studies have demonstrated improvements in daytime saturation and degree of hypercarbia with nocturnal CPAP use.\(^7^5\)\(^,\)\(^7^6\) Improvements in FEV\(_1\), echocardiogram estimates of mean pulmonary artery pressure, PaO\(_2\), and PaCO\(_2\) have been documented.\(^7^5\)\(^,\)\(^7^7\)\(^,\)\(^7^8\) Other studies have found a decline in lung function among patients with OVS who were adherent to CPAP therapy.\(^7^9\) Given the differences in study design, other factors such as weight loss, progression of underlying disease, and selection bias of among those who choose to use CPAP are all important considerations. The reason behind these improvements in gas exchange may reflect an improvement in daytime lung function, though the mechanism remains unclear and controversial. The prevention of repetitive upper airway collapse in an animal model seemed to improve lower airway resistance.\(^8^0\)

Off-loading of respiratory muscles during sleep through CPAP may also be important, contributing to decreased oxygen consumption, CO\(_2\) production, and reducing sleep hypoventilation. After CPAP initiation, fewer COPD-related hospital admissions are seen in some populations.\(^6^3\)\(^,\)\(^8^1\)

As discussed earlier, recent papers suggest that the treatment of OVS with CPAP is associated with reduced mortality. First, in the Brazilian cohort, 5-year survival with CPAP was 71%, as compared with 26% among patients using oxygen alone.\(^6^2\) This cohort included more than 600 patients who required long-term oxygen therapy for hypoxic...
COPD and had at least moderate OSA. Patients with OSA were prescribed CPAP, and those who were nonadherent to CPAP continued to use oxygen for COPD. Similarly, the findings from a Spanish cohort of patients with OVS also suggested a benefit, lowering the mortality risk to that of COPD alone. The striking improvement in both cohorts supports a beneficial role of CPAP as well as highlighting the very poor outcomes in those with OVS. Again, patients in both studies were not randomized but were self-selected based on adherence to CPAP (or were not able to afford CPAP therapy). That is, these are observational studies comparing patients with OVS who are and are not adherent to CPAP. Although these studies do not elicit the mechanism for the reduced mortality, if caused by CPAP, this may be through the reduction in cardiac risk factors. Indeed, CRP levels, a nonspecific marker of inflammation, were significantly reduced in patients with OVS using CPAP as compared with pretreatment.

Noninvasive ventilation (NIV), such as bilevel positive airway pressure, is an attractive treatment modality in this population. Even in the absence of OSA, nocturnal NIV is often applied for patients with more severe COPD to off-load respiratory muscles, supplement ventilation, decrease hypercapnia, and reduce hypoxemia. Studies in this area have generally been small, nonrandomized, and in patients with stable disease. Taken together, these studies did not demonstrate any improvements in lung function, gas, exchange, sleep efficiency, or mortality according to a 2003 meta-analysis. Since that time, however, 2 areas of investigation deserve to be highlighted. Among patients with OVS with stable hypercapnic COPD (patients with OSA were excluded), one moderately large randomized trial demonstrated a mortality benefit with NIV use, though NIV was accompanied by a decrease in quality of life. A mortality benefit compared with historical controls has also been seen using very high ventilation settings. These investigators argue that so-called high-intensity noninvasive positive pressure ventilation (with very high driving pressures, for example, inspiratory pressures of 28 cm of H2O and respiratory rate of more than 20 breaths per minute) among patients with COPD does not seem to impact sleep quality and may have some benefits, such as improvement in gas exchange and lung function.

Weight loss is beneficial among patients with OSA and obesity. Among patients with COPD alone, however, weight loss is often a concerning finding, stemming from pulmonary cachexia, infection, malignancy, or deconditioning. The role of weight loss among patients with OVS has not been examined; however, it is probably safe for obese patients with OVS to target weight loss. Although purely speculative, given the high rates of cardiovascular disease in OSA and COPD, it may also make sense to consider cardioprotective therapies (eg, aspirin, statin) as the primary prevention in patients with OVS.

Based on all of the aforementioned information, the authors propose the diagnostic and treatment algorithm in Fig. 3.

**OSA AND ILD, WITH EMPHASIS ON IPF**

**ILD/IPF Background**

ILD may refer to several heterogeneous conditions, such as IPF; sarcoidosis; autoimmune-related pulmonary disorders, such as systemic sclerosis and hypersensitivity pneumonitis; or secondary to an environmental or drug exposure, such as amiodarone. The common features of the ILDs are (1) that these are distinct from obstructive lung diseases (such as COPD) and demonstrate restrictive physiology and (2) that the anatomic basis of the disease is usually the interstitium (the alveolar epithelium, pulmonary capillary endothelium, basement membrane, perivascular, and peri两年mphatic tissues). The focus of the authors’ discussion is primarily among patients with IPF.

IPF is a restrictive lung disease of unknown cause. It is characterized by chronic, progressive lung fibrosis of unknown cause. It is an irreversible process, with an unpredictable course. Progression can vary markedly on an individual basis, from slow chronic decline to a rapid acceleration of disease; acute exacerbations may also punctuate the disease course. Prognosis is generally very poor, and there are no known effective medical treatments. Despite ongoing research, the cause of the disease remains poorly understood. Histologically, IPF correlates with the pattern of usual interstitial pneumonitis; the terms are sometimes used synonymously.

As compared with COPD, IPF is a rare condition, affecting approximately 14 to 28 per 100,000 people in the United States. It is more common in older individuals and males. The relatively low prevalence of IPF means that, as compared with COPD, the prevalence of coexisting OSA and IPF (or any ILD) is presumably also rare. However, OSA and IPF might be worth studying if (1) IPF predisposes to OSA, (2) symptoms traditionally ascribed to IPF (eg, fatigue) are actually caused by OSA and can be successfully treated with OSA treatment, and (3) treatment of OSA in these patients improves outcomes.
Sleep in IPF

Poor sleep is common among patients with IPF. Global measures of sleep quality and excessive daytime sleepiness are significantly different as compared with controls, with patients with IPF complaining of poor sleep and excessive daytime sleepiness.94 Insomnia is also a frequent occurrence, found in almost one-half of patients with IPF, which may contribute to the high rates of daytime symptoms.95 When sleep is objectively assessed by polysomnography, as compared with controls, patients with IPF have increased sleep fragmentation and stage I sleep.96–98 Total sleep time, sleep efficiency, and REM sleep are all reduced.96–98

The mechanisms for these sleep abnormalities remain incompletely understood, though are likely to be multifactorial. Disruption from cough has been frequently cited as one factor that contributes to sleep disturbance and the inability to sleep.95,99–101 The effect of medications, such as corticosteroids, which are still used empirically given the lack of other treatment options, may further contribute to some of the sleep abnormalities reported by patients with IPF. Nearly two-thirds of patients in one series were on prednisone,94 which may interfere with sleep when used at high doses. Patients with IPF are often additionally burdened by depression and other mood disorders, which are often characterized by sleep disturbances and changes in energy level; the medications used to treat these disorders may also impact sleep and daytime function.

Respiration During Sleep in IPF

The pathologic changes in pulmonary fibrosis are decreased lung compliance and increased ventilation/perfusion mismatch. These changes will increase minute ventilation and the work of breathing. As a result, patients with IPF exhibit rapid, shallow breathing during wakefulness.98 During sleep, the tachypnea persists; as compared with normal controls, there is no decrease in respiratory rate, although tidal volume decreases.96 Thus, similar to COPD as discussed earlier, among patients with ILD, sleep may serve as a stressor to the respiratory system. Oxygen desaturation is frequently more profound than during wakefulness. The importance of evaluating nighttime respiratory patterns has been recently highlighted, as it may have prognostic value in assessing mortality in ILD.102 Specifically, among
patients with newly diagnosed IPF, the degree of nocturnal desaturation was greater than seen during exercise and was predictive of survival.\textsuperscript{103–105} Possibly mediated through worsening pulmonary artery hypertension.\textsuperscript{103}

**ILD and Sleep-Disordered Breathing**

The prevalence of sleep-disordered breathing is reported to be extraordinarily high among patients with ILD. Symptoms such as fatigue, commonly reported in patients with IPF, may be attributable to this.\textsuperscript{109} In published series, the incidence of OSA ranges from more than two-thirds to nearly 90%.\textsuperscript{106–108} Fig. 4 outlines the symptoms that are commonly reported in IPF and how they may overlap with OSA. The nature of OSA in these populations remains incompletely characterized, such as whether events are caused by airway collapse and flow limitation or oxygen desaturations. Among patients with IPF, AH\textsubscript{I} is not strongly correlated with the body mass index, again suggesting that other mechanisms, aside from obesity, may be contributing to the diagnosis of OSA in this population.\textsuperscript{108} Indeed, as compared with controls, patients with IPF spend more time with an oxygen saturation less than 90%, even when the AH\textsubscript{I} is similar. These observations raise the possibility that the lower baseline oxygen saturation and increased tendency toward desaturation are overestimating the collapsibility of the upper airway. The 2009 study by Lancaster and colleagues\textsuperscript{108} is helpful in this regard. First, their subjects with mild OSA had a mean AH\textsubscript{I} of 10.7 events per hour, of which less than 1 event per hour was apnea. Additionally, approximately half of the hypopneas were scored based on a 3% oxygen desaturation (rather than arousal). In those with moderate to severe OSA, the average AH\textsubscript{I} was 39.4 events per hour. But again, the apnea index was only 7.1 events per hour; nearly half of all hypopneas were scored based on oxygen desaturation.

In support of a mechanistic link between IPF and OSA, some investigators have invoked so-called tracheal traction, the link between lung volumes and the upper airway.\textsuperscript{109,110} Briefly, in patients without lung disease, a decrease in lung volumes leads to increased upper airway resistance, increased collapsibility, and worse OSA severity.\textsuperscript{111,112} However, whether this relationship still holds when compliance of the lung is altered is not clear; no formal measurement of airway resistance or collapsibility has been made in patients with IPF to test this hypothesis. Again, in the study by Lancaster and colleagues,\textsuperscript{108} total lung capacity did not seem to predict OSA.

**Treatment**

There are no proven therapies that target the underlying disease process in IPF. Oxygen therapy is widely used as supportive care. Studies suggest that oxygen therapy can be associated with improvements in exercise performance.\textsuperscript{113,114} However, no studies have demonstrated a mortality benefit\textsuperscript{115} or improvement in exertional dyspnea,\textsuperscript{116} as rapid shallow breathing persists despite addressing hypoxemia.

Treatment with CPAP among patients with IPF with at least moderate OSA results in gains in sleep-related quality-of-life measures, though adherence to CPAP may be challenging in light of chronic cough and other barriers.\textsuperscript{117} There are no studies that have explored the impact of CPAP on outcomes in IPF, such as disease progression or mortality. Taken together, OSA may be common in IPF; treatment with CPAP may improve OSA symptoms.

**Other OVS: Beyond COPD and IPF**

From the earlier discussion, it is clear that there are many research and clinical questions that remain for OVS, even for the OVS, which is relatively common. Even less is known about the prevalence, consequences, and best management of OSA among other chronic lung diseases. However, there are some pearls that the sleep physician should know regarding other lung diseases.

Sarcoidosis is a chronic condition of unknown cause characterized by the formation of granulomas in many organs, most commonly the lung. Lung disease may range from mild to severe and fibrosing in nature. Steroids are often given in more severe disease. Fatigue and excessive daytime sleepiness are more common among patients with sarcoid compared with controls.\textsuperscript{118–120} Consideration of OSA among these patients is.
therefore, important, particularly among those with abnormal lung function. There is a population of patients, however, with hypopneumonolence unrelated to OSA. Relevant for sleep medicine practitioners, fatigue improves with stimulant therapy (armodafinil). This improvement may serve as a paradigm for patients with chronic lung disease and fatigue to receive empiric therapy.

Although most of the data are in pediatric populations, OSA seems to be more common among patients with sickle cell anemia as compared with controls. OSA among patients with sickle cell disease is accompanied by more severe nocturnal desaturations and hypercarbia. Although larger studies are needed to better describe the relationship, OSA, through nocturnal hypoxia, may serve as a trigger for vasoocclusive sickle events. This highlights the potential importance of recognizing and treating OSA among those with sickle cell disease.

Cystic fibrosis (CF) is a systemic disease characterized by abnormal chloride channel function. Obstructive lung disease, including bronchiectasis and repeated pulmonary infections caused by tenacious sputum, are common in among patients with CF. Sleep apnea is common (in up to 70% of children with CF). OSA presents at an early age as compared with controls, as young as preschool age. NOD is also common among patients with CF, particularly those with awake oxygen saturation less than 94%.

**SUMMARY**

The combination of chronic lung disease and OSA in a single patient is still, as yet, poorly understood. Many research and clinical questions remain, including how best to quantify upper airway collapsibility and sleep fragmentation in patients already at risk for hypoxemia caused by chronic lung disease. These questions must be answered given the high prevalence of the OVS, COPD and OSA, and observational cohort studies that show very high mortality without OSA treatment.

Other chronic lung diseases, such as IPF, are much less common; yet diagnosis and treatment of OSA may be important. Within these patient populations, there are few or no therapies available to target the underlying disease and its consequences. Recognition and treatment of OSA, therefore, could offer key benefits, such as improvements in quality of life or fatigue level.

**REFERENCES**

Dudley et al


46. Lewis CA, Fergusson W, Eaton T, et al. Isolated nocturnal desaturation in COPD: prevalence and...


74. Loredo JS, Ancoli-Israel S, Kim EJ, et al. Effect of continuous positive airway pressure versus
Dudley et al


Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult http://www.elsevier.com/artworkinstructions.

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof.

<table>
<thead>
<tr>
<th>Location in article</th>
<th>Query / Remark: Click on the Q link to find the query’s location in text</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Q1</strong></td>
<td>Please approve the short title to be used in the running head at the top of each right-hand page.</td>
</tr>
<tr>
<td><strong>Q2</strong></td>
<td>This is how your name will appear on the contributor’s list. Please add your academic title and any other necessary titles and professional affiliations, verify the information, and OK KATHERINE A. DUDLEY, MD, Boston, Massachusetts ATUL MALHOTRA, MD, Boston, Massachusetts ROBERT L. OWENS, MD, Boston, Massachusetts</td>
</tr>
<tr>
<td><strong>Q3</strong></td>
<td>Are author names and order of authors OK as set?</td>
</tr>
<tr>
<td><strong>Q4</strong></td>
<td>The affiliation is not provided for the authors “Katherine A. Dudley” and “Atul Malhotra”, hence the provided corresponding author affiliation address has been retained for both the authors. Please verify and provide the affiliation for the above mentioned authors.</td>
</tr>
<tr>
<td><strong>Q5</strong></td>
<td>The following synopsis was created from the “Key points” section of your article because a separate abstract was not provided. Please confirm OK or submit a replacement (also less than 100 words). Please note that the synopsis will appear in PubMed: Overlap syndrome refers to the coexistence of chronic lung disease and obstructive sleep apnea (OSA) in the same patient. Recent data in chronic obstructive pulmonary disease and patients with OSA overlap highlight the increased morbidity and mortality of overlap syndromes compared with either underlying disorder alone. The underlying disorders in overlap syndrome may be of very different severity; thus, there is a great amount of patient heterogeneity. Unrecognized OSA may contribute to symptoms of sleepiness and fatigue in those with chronic lung disease. Thus, clinicians should be mindful of the overlap syndromes in these patients.</td>
</tr>
<tr>
<td><strong>Q6</strong></td>
<td>Please verify the affiliation address and provide the missing information (department name, University/Institute/Center).</td>
</tr>
<tr>
<td><strong>Q7</strong></td>
<td>Please check the article to be sure the edits preserve your intent.</td>
</tr>
</tbody>
</table>

(continued on next page)
If there are any drug dosages in your article, please verify them and indicate that you have done so by initialing this query.

Per Clinics style, quotation marks are only used to offset a direct quote, to define a word, and in certain titles. Therefore, the quotation marks that seem to be used for emphasis have been removed. Please verify that the edit preserves your intent.

Per Clinics style, abbreviations are introduced at the first mention of the term and then are used thereafter throughout the article in place of the spelled out term. Therefore, all instances of “overlap syndrome” have been replaced with the abbreviation OVS. Please verify that the edit preserves your intent.

Please verify that the hierarchy of the heading levels is OK as set.

Please clarify “selection bias of among” in the sentence beginning “Given the differences…”

Please verify that the term “males” refers to both adults and children. Per Clinics style, the noun males is only used when discussing both adults and children. If only adults are meant, the term men should be used.

Please clarify what is meant by “This” in the sentence beginning “This highlights the potential…” Per Clinics style, when the term This begins a sentence, it is followed by a noun.

Please clarify “common in among” in the sentence beginning “Obstructive lung disease…”

Originally Refs. [21, 59] and [58, 60] were identical, hence the latter has been removed from the reference list and subsequent references have been renumbered. Please verify.

Please verify that the edits to Table 1 preserve your intent.

Please spell out “SpO2” in Table 1.

Please cite footnote “a” in Table 1.

In all credit lines that require permission, please provide the exact page numbers from which the information was taken.

Please spell out HTN and PFT in Fig. 3.

Thank you for your assistance.